DefinitionThis section has been translated automatically.
Synthetic peptidomimetic which acts as an antagonist by blocking the bradykinin B2 receptor.
Field of application/useThis section has been translated automatically.
Icatibant has been approved for the treatment of bradykinin-associated angioedema in Europe (by the European Medicines Agency [EMA]). In several clinical trials, subcutaneous application of 30 mg s.c. Icatibant (FAST-1/2 study) has shown significantly better results than the comparatively applied antifibrinolytic tranexamic acid.
You might also be interested in
IndicationThis section has been translated automatically.
Approved throughout Europe by the EMA for the treatment of acute attacks of hereditary angioedema in adults with C1 esterase inhibitor deficiency. Off-label use exists for use outside this indication.
Dosage and method of useThis section has been translated automatically.
Single dose of 30 mg s.c.
PreparationsThis section has been translated automatically.
Firazyr®
Note(s)This section has been translated automatically.
Bradykinin is an endogenous peptide-based hormone that is produced locally in response to trauma. It increases vascular permeability, dilates blood vessels, leads to the contraction of smooth muscle cells and plays an essential role in the transmission of pain. Bradykinin is responsible for the typical inflammatory symptoms such as swelling, redness, hyperthermia and pain. These symptoms are mediated by the activation of bradykinin B2 receptors.
LiteratureThis section has been translated automatically.
- Bork K et al (2007) Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant) J Allergy Clin Immunol 119: 1497-1503
Prof. Dr. med. Peter Altmeyer